Literature DB >> 30154106

Evaluation of Organic Anion Transporter 1A2-knock-in Mice as a Model of Human Blood-brain Barrier.

Yamato Sano1, Tadahaya Mizuno1, Tatsuki Mochizuki1, Yasuo Uchida1, Mina Umetsu1, Tetsuya Terasaki1, Hiroyuki Kusuhara2.   

Abstract

The present study aimed to establish a humanized mouse model with which to explore OATP1A2-mediated transcellular transport of drug substrates across the blood-brain barrier (BBB) and to evaluate the usefulness of the humanized mice in preclinical studies. Sulpiride, amisulpride, sultopride, and triptans were used as probes to discriminate OATP1A2 and Oatp1a4. We generated a mouse line humanized for OATP1A2 by introducing the coding region downstream of the Oatp1a4 promoter using the CRISPR/Cas9 technique. In the mice generated, OATP1A2 mRNA in the brain was increased corresponding to disappearance of Oatp1a4. OATP1A2 was localized on both the luminal and abluminal sides of the BBB. Unfortunately, study in vivo employing sulpiride, sumatriptan, and zolmitriptan as probes did not indicate any difference in their brain-to-plasma ratio between the control and humanized mice. Quantitative targeted absolute proteomic analysis of the BBB fraction from the humanized mice revealed that almost all analyzed transporters and membrane proteins were expressed at similar levels to those in control mice. The quantitative levels of OATP1A2 differed depending on the peptide quantified, which suggests that incomplete translation or posttranslational modification may occur. The blood-to-brain transport of zolmitriptan, determined by brain perfusion in situ, was 1.6-fold higher in the humanized mice than in the controls, whereas that of sulpiride was not significantly changed. To our knowledge, we established a mouse line humanized for a BBB uptake transporter for the first time. Unfortunately, because of limited impact, there is still room for improvement of the model system.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30154106     DOI: 10.1124/dmd.118.081877

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier.

Authors:  Raymond K Hau; Robert R Klein; Stephen H Wright; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2022-03-20       Impact factor: 3.579

Review 2.  Application of CRISPR-Cas9 System to Study Biological Barriers to Drug Delivery.

Authors:  Ji He; Riya Biswas; Piyush Bugde; Jiawei Li; Dong-Xu Liu; Yan Li
Journal:  Pharmaceutics       Date:  2022-04-20       Impact factor: 6.525

3.  Transport Properties of Statins by Organic Anion Transporting Polypeptide 1A2 and Regulation by Transforming Growth Factor-β Signaling in Human Endothelial Cells.

Authors:  Patrick T Ronaldson; Hrvoje Brzica; Wazir Abdullahi; Bianca G Reilly; Thomas P Davis
Journal:  J Pharmacol Exp Ther       Date:  2020-11-09       Impact factor: 4.030

4.  Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.

Authors:  Katherine D Lynch; Michelle L Montonye; Dan-Dan Tian; Tarana Arman; Victoria O Oyanna; Baron J Bechtold; Tyler N Graf; Nicholas H Oberlies; Mary F Paine; John D Clarke
Journal:  Phytother Res       Date:  2021-02-15       Impact factor: 6.388

5.  The year in review: progress in brain barriers and brain fluid research in 2018.

Authors:  Richard F Keep; Hazel C Jones; Lester R Drewes
Journal:  Fluids Barriers CNS       Date:  2019-02-05

Review 6.  Transport Mechanisms at the Blood-Brain Barrier and in Cellular Compartments of the Neurovascular Unit: Focus on CNS Delivery of Small Molecule Drugs.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmaceutics       Date:  2022-07-20       Impact factor: 6.525

Review 7.  Expression and Function of Organic Anion Transporting Polypeptides in the Human Brain: Physiological and Pharmacological Implications.

Authors:  Anima M Schäfer; Henriette E Meyer Zu Schwabedissen; Markus Grube
Journal:  Pharmaceutics       Date:  2021-06-04       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.